New aspects of injectable contraception

Int J Fertil Womens Med. 2001 Jan-Feb;46(1):31-6.

Abstract

Despite the availability of efficacious and safe contraceptive agents, not all women's contraceptive needs are being met. An injectable contraceptive method offers convenience and encourages compliance, both very important aspects for women seeking ideal contraception. Depot medroxyprogesterone acetate (DMPA) is a long-acting injectable, and is highly effective; one injection provides 3 months of contraception. Drawbacks of DMPA include irregular bleeding and a slow return to fertility. A new monthly injectable contraceptive agent is medroxyprogesterone acetate/estradiol cypionate suspension (Lunelle). It provides menstrual regulation and a rapid return to fertility. The estrogen ensures a withdrawal bleed monthly; however, women with contraindications to estrogen-containing contraception are not candidates for Lunelle.

Publication types

  • Review

MeSH terms

  • Contraception / methods*
  • Contraceptive Agents, Female / administration & dosage*
  • Contraceptive Agents, Female / adverse effects
  • Delayed-Action Preparations
  • Drug Administration Schedule
  • Estradiol / administration & dosage*
  • Estradiol / adverse effects
  • Estradiol / analogs & derivatives*
  • Female
  • Humans
  • Injections, Intramuscular
  • Medroxyprogesterone Acetate / administration & dosage*
  • Medroxyprogesterone Acetate / adverse effects
  • Patient Compliance
  • Safety

Substances

  • Contraceptive Agents, Female
  • Delayed-Action Preparations
  • Lunelle
  • Estradiol
  • Medroxyprogesterone Acetate